Zobrazeno 1 - 10
of 596
pro vyhledávání: '"Jürgen, Finke"'
Autor:
Ann-Kristin Schmälter, Maud Ngoya, Jacques-Emmanuel Galimard, Ali Bazarbachi, Jürgen Finke, Nicolaus Kröger, Martin Bornhäuser, Matthias Stelljes, Friedrich Stölzel, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor-Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Second allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date
Externí odkaz:
https://doaj.org/article/8ce62a1bb95843f1806c32fcdc1eed21
Autor:
Miriam Mozaffari Jovein, Gabriele Ihorst, Jesús Duque-Afonso, Ralph Wäsch, Hartmut Bertz, Claudia Wehr, Justus Duyster, Robert Zeiser, Jürgen Finke, Florian Scherer
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Primary induction failure (PIF) in acute myeloid leukemia (AML) patients is associated with poor outcome, with allogeneic hematopoietic stem cell transplantation (HCT) being the sole curative therapeutic option. Here, we retrospectively eval
Externí odkaz:
https://doaj.org/article/b0c4ddf6437348259a83d0ec04d80321
Autor:
Sabine Blum, Yves Chalandon, Myriam Labopin, Jürgen Finke, Tobias Gedde-Dahl, Tarek Ben Othman, Jan J. Cornelissen, Pavel Jindra, Hélène Labussière-Wallet, Matthew Collin, Stig Lenhoff, Guido Kobbe, Norma C. Gutiérrez, Arnon Nagler, Mohamad Mohty
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/33b53f37a16444f98acbf1e05d2e0edf
Autor:
Lisa K Isbell, Roswitha Uibeleisen, Alexander Friedl, Elvira Burger, Tatja Dopatka, Florian Scherer, Andras Orban, Eliza Lauer, Natalie Malenica, Inna Semenova, Annika Vreden, Elke Valk, Julia Wendler, Simone Neumaier, Heidi Fricker, Abed Al Hadi El Rabih, Cora Gloggengießer, Daniela Hilbig, Sabine Bleul, Joachim Weis, Dennis Gmehlin, Matthias Backenstrass, Sebastian Wirtz, Gabriele Ihorst, Jürgen Finke, Gerald Illerhaus, Elisabeth Schorb
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Older primary central nervous system lymphoma (PCNSL) patients have an inferior prognosis compared to younger patients because available evidence on best treatment is scarce and treatment delivery is challenging due to comorbiditi
Externí odkaz:
https://doaj.org/article/12be11ae6eaa40df980e3443b49886e9
Autor:
Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas Kulozik, Joachim Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper, Martin Görner, Jürgen Finke, Andreas Neubauer, Mark Ringhoffer, Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-17 (2023)
Abstract Background Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 invest
Externí odkaz:
https://doaj.org/article/26e8df351a78481d84b79ca3e21d57c8
Autor:
Jan Frederic Weller, Claudia Lengerke, Jürgen Finke, Johannes Schetelig, Uwe Platzbecker, Hermann Einsele, Thomas Schroeder, Christoph Faul, Matthias Stelljes, Peter Dreger, Igor W. Blau, Gerald Wulf, Johanna Tischer, Christoph Scheid, Ahmet Elmaagacli, Helga Neidlinger, Sarah Flossdorf, Martin Bornhäuser, Wolfgang Bethge, Katharina Fleischhauer, Nicolaus Kröger, Liesbeth C. de Wreede, Maximilian Christopeit
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,4
Externí odkaz:
https://doaj.org/article/fc1be0b091ba420e8bdda5a14ed93bf6
Autor:
Marie Robin, Liesbeth C. de Wreede, Thomas Schroeder, Friedrich Stölzel, Nicolaus Kröger, Linda Koster, Uwe Platzbecker, Jürgen Finke, Arnold Ganser, Didier Blaise, Fabio Ciceri, Johan Maertens, Hélène Labussière Wallet, Junfeng Wang, Patrice Chevallier, Jakob Passweg, Jan J Cornelissen, Stéphanie Nguyen, Edouard Forcade, Amandine Charbonnier, Francesca Bonifazi, Patrick Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha
Publikováno v:
HemaSphere, Vol 7, Iss 4, p e851 (2023)
Externí odkaz:
https://doaj.org/article/e03e259b51fd42bdbcd057a17717db7b
Autor:
Thomas Meyer, Gabriele Ihorst, Ingrid Bartsch, Robert Zeiser, Ralph Wäsch, Hartmut Bertz, Jürgen Finke, Daniela Huzly, Claudia Wehr
Publikováno v:
Vaccines, Vol 10, Iss 11, p 1782 (2022)
To determine factors influencing the vaccination response against SARS-CoV-2 is of importance in recipients of allogeneic hematopoietic cell transplantation (allo-HCT) as they display an increased mortality after SARS-CoV-2 infection, an increased ri
Externí odkaz:
https://doaj.org/article/e5907ab6a3a8422ab8a46b62d1df13ee
Autor:
Joshua A. Fein, Roni Shouval, Jacques-Emmanuel Galimard, Myriam Labopin, Gérard Socié, Jürgen Finke, Jan J. Cornelissen, Ram Malladi, Maija Itälä-Remes, Patrice Chevallier, Kim H. Orchard, Donald Bunjes, Mahmoud Aljurf, Marie Thérèse Rubio, Jurjen Versluis, Mohamad Mohty, Arnon Nagler
Publikováno v:
Blood Advances. 7:2143-2152
Older age and a high burden of comorbidities often drive the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. However, the impact of comorbidities in the low-intensity conditioning set
Autor:
Miguel Waterhouse, Sandra Pennisi, Dietmar Pfeifer, Florian Scherer, Robert Zeiser, Justus Duyster, Hartmut Bertz, Jürgen Finke, Jesús Duque-Afonso
Publikováno v:
Cancers, Vol 14, Iss 14, p 3307 (2022)
Relapse of the underlying disease is a frequent complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we describe the clinical utility of measurable residual disease (MRD) and mixed chimerism (MC) assessmen
Externí odkaz:
https://doaj.org/article/d047753c329d43b2bb438c28646cefe1